Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Popat R, Oriol A, Cavo M, Karlin L, Mazza I, Roeloffzen W, Kim S, Lipe B, Bar N, Horvath N, Spencer A, Min C, Chen D, Li Q, Li K, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Lendvai N, Lengil T, Patel N, Filho O, Florendo E, Lin Y. Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial. Blood 2024, 144: 1032. DOI: 10.1182/blood-2024-201533.Peer-Reviewed Original ResearchMinimal residual disease negativityMRD-negativity ratesSustained MRD negativityMinimal residual diseaseProgression-free survivalMedian progression-free survivalCilta-celMRD negativitySOC armOverall survivalMultiple myelomaInterim analysisPost-infusionFollow-upMinimal residual disease assessmentMinimal residual disease dataMinimal residual disease positivityCilta-cel infusionProlonged survival outcomesMedian follow-upOverall response rateNegative resultsStandard of careMedian OSComplete response